RPRX

Repros Therapeutics Inc.

RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

Back to rankings

Healthcare Drug Manufacturers - General

Financial journalist opinion

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million.

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalties to Royalty Pharma for up to $65 million within the next 12 months.

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen's IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX). Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to.

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021.

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

Royalty Pharma: Keep Delivering, Buy Confirmed

Robust quarterly performance with royalty receipts and adjusted EBITDA by +11% and +13%, respectively. New catalysts are emerging with recurrent billion‑dollar transactions and Chinese royalty opportunities. Shareholder returns remain strong and are combined with a valuation discount. We remain buyers.

Royalty Pharma: Keep Delivering, Buy Confirmed

The Motley Fool

Royalty Pharma (RPRX) Q2 Receipts Up 20%

Royalty Pharma (RPRX) Q2 Receipts Up 20%

Royalty Pharma (RPRX) Q2 Receipts Up 20%

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Royalty Pharma plc (NASDAQ:RPRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Marshall Jonathan Urist - Executive Vice President of Research & Investments Pablo Gerardo Legorreta - Founder, Chairman of the Board & CEO Terrance P. Coyne - Executive VP & CFO Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Christopher Thomas Schott - JPMorgan Chase & Co, Research Division Geoffrey Christopher Meacham - Citigroup Inc., Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings

Zacks Investment Research

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.96 per share a year ago.

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma Reports Second Quarter 2025 Results

Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $364 million Raised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “We delivered excellent second quarter 2025 results, as the strength of our diversified portfolio drove 20% growth in Portfolio Receipts, and raised our full year guidance,” said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer.

Royalty Pharma Reports Second Quarter 2025 Results

See News Rankings

Charts implemented using Lightweight Charts™